Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
NabumetoneF1 I SEP / 98
Nadolol and its saltsF1 I SEP / 98
Nadroparin and its saltsF1 I SEP / 99
Nafarelin and its salts and derivativesF1 I SEP / 98
Nalbuphine and any salt thereofC2 I JUN / 02
Nalidixic acidF1 I SEP / 98
Nalmefene and its saltsF1 I SEP / 99
NalorphineN I JUN / 02
Naloxegol or its saltsPDL

including but not limited to naloxegol oxalate

I JUN / 15
Naloxone hydrochloride injection,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone hydrochloride nasal spray,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone or its saltsPDL

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

I FEB / 17
Naltrexone and its salts and derivativesF1 I OCT / 09
NandroloneC3 I JUN / 02
Naphazoline and its salts in nasal preparations for pediatric use II SEP / 98
Naphazoline and its salts. in nasal preparations for adult use and in ophthalmic products U
Naproxen or its saltsPDL

except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base)

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

I MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

U MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

III MAR / 15
Naratriptan and its saltsF1 I SEP / 99
Narcotine and its salts Noscapine III SEP / 98
NatalizumabF1 I APR / 08
Nateglinide and its salts and derivativesF1 I OCT / 03
NecitumumabPDL I APR / 17
Nedocromil and its saltsF1 I SEP / 98
Nefazodone and its saltsF1 I SEP / 98
NelarabineF1 I MAY / 10
Nelfinavir and its saltsF1 I SEP / 99
Neocinchophen and its saltsF1 I SEP / 98
Neomycin and its salts and derivativesF2 I SEP / 98
Neostigmine saltsF1 I SEP / 98
NepafenacF1 I OCT / 09
Nesiritide or its saltsPDL I DEC / 13
Netilmicin and its salts and derivativesF1 I SEP / 98
Nevirapine and its saltsF1 I MAY / 00
Niacin in extended-release formulations nicotinic acid II DEC / 98
Niacin. in immediate-release formulations U DEC / 98
Niacinamide for topical use U OCT / 98
Niacinamide. oral U OCT / 98
Nialamide and its saltsF1 I SEP / 98
NicarbazinF2 I SEP / 98
Nicardipine and its saltsF1 I SEP / 98
NicocodineN I JUN / 02
NicomorphineN I JUN / 02
Nicotine and its salts, for human useF1

(except: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit. )

I JUN / 06
Nicotine and its salts.

when sold as a chewing gum containing not more than the equivalent of 4 mg of nicotine per dosage unit

U NOV / 00
Nicotine and its salts..

when sold as a transdermal patch with a delivery rate of not more than the equivalent of 22 mg

U NOV / 00
Nicotine and its salts...

when sold in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit

U JAN / 05
Nicotine and its salts....

when sold in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

U JUN / 06
Nicotinic acidF1 When sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose I JUN / 08
Nicotinyl-tartrate I SEP / 98
NifedipineF1 I SEP / 98
Nikethamide I SEP / 98
Nilotinib and its saltsF1 I MAY / 10
NilutamideF1 I SEP / 98
NimetazepamTS I JUN / 02
Nimodipine and its saltsF1 I SEP / 98
Nintedanib or its saltsPDL I AUG / 15
NitisinonePDL I NOV / 16
Nitrazepam and its saltsTS I SEP / 98
Nitric oxideF1 I FEB / 07
Nitrofurantoin and its saltsF2 I SEP / 98
Nitroglycerin except for sublingual immediate release dosage forms I SEP / 98
Nitroglycerin. sublingual immediate release dosage forms II SEP / 98
NitroscanateF1 I MAY / 00
NivolumabPDL I JAN / 16
Nizatidine and its saltsF1 except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine I SEP / 98
Nizatidine and its salts when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine* I SEP / 98
Nomifensine and its saltsF1 I SEP / 98
NoracymethdolN I JUN / 02
NorboletoneC3 I JUN / 02
NorclostebolC3 I JUN / 02
NorcodeineN I JUN / 02
NordazepamTS I JUN / 02
Norepinephrine and its salts levarterenol, noradrenaline II SEP / 98
NorethandroloneC3 I JUN / 02
NorfloxacinF1 I SEP / 98
NorlevorphanolN I JUN / 02
NormethadoneN I JUN / 02
NormorphineN I JUN / 02
NorpethidineN I JUN / 02
NorpipanoneN I JUN / 02
Nortriptyline and its saltsF1 I SEP / 98
Noscapine III SEP / 98
Novobiocin and its salts and derivativesF2 I SEP / 98
NusinersenPDL I AUG / 17
Nylidrin and its saltsF1 I SEP / 98
Nystatin and its salts and derivativesF2 except preparations for topical use on the skin I SEP / 98
Nystatin and its salts and derivatives. in topical preparations for use on the skin III SEP / 98

89 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled